MABS485 Sigma-AldrichAnti-Ido1, clone 8G11 Antibody
Anti-Ido1, clone 8G11 Antibody is an antibody against Ido1 for use in Western Blotting, Flow Cytometry.
More>> Anti-Ido1, clone 8G11 Antibody is an antibody against Ido1 for use in Western Blotting, Flow Cytometry. Less<<Anti-Ido1, clone 8G11 Antibody MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
UniProt Number: P14902
Recommended Products
概述
| Replacement Information | 
|---|
重要规格表
| Species Reactivity | Key Applications | Host | Format | Antibody Type | 
|---|---|---|---|---|
| M | WB, FC | M | Purified | Monoclonal Antibody | 
| References | 
|---|
| Product Information | |
|---|---|
| Format | Purified | 
| Presentation | Purified mouse monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. | 
| Quality Level | MQ100 | 
| Physicochemical Information | 
|---|
| Dimensions | 
|---|
| Materials Information | 
|---|
| Toxicological Information | 
|---|
| Safety Information according to GHS | 
|---|
| Safety Information | 
|---|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. | 
| Packaging Information | |
|---|---|
| Material Size | 100 µg | 
| Transport Information | 
|---|
| Supplemental Information | 
|---|
| Specifications | 
|---|
| Global Trade Item Number | |
|---|---|
| 产品目录编号 | GTIN | 
| MABS485 | 04055977136869 | 
Documentation
Anti-Ido1, clone 8G11 Antibody MSDS
| 职位 | 
|---|
Anti-Ido1, clone 8G11 Antibody 分析证书
| 标题 | 批号 | 
|---|---|
| Anti-Ido1, clone 8G11 - 3193866 | 3193866 | 
| Anti-Ido1, clone 8G11 - 3389912 | 3389912 | 
| Anti-Ido1, clone 8G11 - 3728241 | 3728241 | 
| Anti-Ido1, clone 8G11 - 3839054 | 3839054 | 
| Anti-Ido1, clone 8G11 - 4034285 | 4034285 | 
| Anti-Ido1, clone 8G11 - 4201251 | 4201251 | 
| Anti-Ido1, clone 8G11 -2817484 | 2817484 | 
| Anti-Ido1, clone 8G11 -Q2556989 | Q2556989 | 
| Anti-Ido1, clone 8G11 Monoclonal Antibody | 2930086 | 
技术信息
| 标题 | 
|---|
| White Paper: Further considerations of antibody validation and usage. | 

 


 
  

 

 
 
 
 
 
 
 
 
